Potent s-cis-locked bithiazole correctors of DeltaF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy
about
Chloride channels as drug targets.Potentiation of ΔF508- and G551D-CFTR-Mediated Cl- Current by Novel HydroxypyrazolinesDesign and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein DeltaF508-CFTRPyrazolylthiazole as DeltaF508-cystic fibrosis transmembrane conductance regulator correctors with improved hydrophilicity compared to bithiazoles.Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists.Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy.Constrained bithiazoles: small molecule correctors of defective ΔF508-CFTR protein trafficking.ΔF508-CFTR correctors: synthesis and evaluation of thiazole-tethered imidazolones, oxazoles, oxadiazoles, and thiadiazoles.Insulin-like growth factor 1 (IGF-1) enhances the protein expression of CFTR.Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis.Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTRF508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.Fluorinated ΔF508-CFTR correctors and potentiators for PET imaging.Structure-activity relationships of cyanoquinolines with corrector-potentiator activity in ΔF508 cystic fibrosis transmembrane conductance regulator protein7-Substituted 8-aza-7-deazaadenosines for modification of the siRNA major grooveClick-based synthesis of triazolobithiazole ΔF508-CFTR correctors for cystic fibrosis.CFTR: folding, misfolding and correcting the ΔF508 conformational defect.Isoxazolopyrimidines as Novel ΔF508-CFTR CorrectorsMechanism-based corrector combination restores ΔF508-CFTR folding and function.Cystic fibrosis transmembrane regulator correctors and potentiators.Phenylhydrazones as Correctors of a Mutant Cystic Fibrosis Transmembrane Conductance Regulator.CFTR pharmacology.The search for a common structural moiety among selected pharmacological correctors of the mutant CFTR chloride channel.Rescuing ΔF508 CFTR with trimethylangelicin, a dual-acting corrector and potentiator.The influence of intramolecular sulfur-lone pair interactions on small-molecule drug design and receptor binding.Molecular basis of cystic fibrosis: from bench to bedside
P2860
Q24601830-1372155C-87F1-4324-92ED-9F140157FA1FQ28550065-CAE1F976-8FBF-4147-9FD5-2FEF182114E4Q30940037-0779970F-8CF7-45AE-ACFA-CF7617CF0DA3Q33550492-0DAEC45D-A563-46BC-ACC8-4EDDE8B6AB1EQ33593241-85B6006E-1211-4ED1-A899-BAC11F4026D4Q33742766-FE23592B-259C-4111-86CB-0ACAEA50A100Q34061088-3A1D8FC1-79DA-475E-B974-044D0AE0C765Q34628552-8394EE26-3204-44CE-8201-E771069FAFC2Q34652853-05924BDA-27BD-4287-8704-4DAF7C7F51CAQ35275305-64E3E2D5-C3A7-4A3D-A992-15887B89B3A5Q35275697-21C7B6AC-9218-412D-A7A5-B176BA52F877Q35630919-41191CDD-2AA8-40BE-B316-51A9E5F2000EQ35742709-8185C12B-CFC5-424D-8BAB-832255DE0F47Q35750147-9333C7BB-B869-41FD-9C7F-E9D41CA82D80Q36160120-DC0E0C40-1173-45CA-AE01-59FA94365ECAQ36166335-2E0600AF-C479-448C-9396-677E188358F9Q36814102-CB0EF7A1-3541-4B98-A5C8-012421BDF425Q36869835-BC894950-8E3E-4A4F-BA05-FD4B5222B5F9Q37341854-8085318A-C16B-43C7-BB2C-A98389D4932FQ38118742-0FFFDCCD-B21F-421B-A342-99F60EAAF0A5Q38809280-4E7D7E63-3AC9-4F8E-92A5-3BA7D209CD47Q38972431-07826A68-4254-478E-9695-E46CCE4F6AE8Q39077956-F5BE32BE-1F6B-4D1E-B983-62C6313B2CD0Q44455766-7529CEBB-4C69-4B45-8278-C22A8D206EF5Q46091880-1FB2BF70-A227-44E0-9A11-010844E5AC81Q57300566-25B2FBB2-5EAA-47F9-B1A7-05B05E7F35DB
P2860
Potent s-cis-locked bithiazole correctors of DeltaF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Potent s-cis-locked bithiazole ...... ng for cystic fibrosis therapy
@ast
Potent s-cis-locked bithiazole ...... ng for cystic fibrosis therapy
@en
type
label
Potent s-cis-locked bithiazole ...... ng for cystic fibrosis therapy
@ast
Potent s-cis-locked bithiazole ...... ng for cystic fibrosis therapy
@en
prefLabel
Potent s-cis-locked bithiazole ...... ng for cystic fibrosis therapy
@ast
Potent s-cis-locked bithiazole ...... ng for cystic fibrosis therapy
@en
P2093
P2860
P356
P1476
Potent s-cis-locked bithiazole ...... ng for cystic fibrosis therapy
@en
P2093
A S Verkman
Baoxue Yang
Choong L Yoo
Dean J Tantillo
Gui Jun Yu
James C Fettinger
Liping Meng
Mark J Kurth
Michael W Lodewyk
Tamer T El-Idreesy
P2860
P304
P356
10.1021/JM800533C
P407
P577
2008-09-13T00:00:00Z